Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 2
2016 1
2017 3
2018 6
2019 6
2020 8
2021 11
2022 6
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
Suda G, Baba M, Yamamoto Y, Sho T, Ogawa K, Kimura M, Hosoda S, Yoshida S, Kubo A, Fu Q, Yang Z, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Kobayashi T, Tsunematsu I, Sakamoto N. Suda G, et al. Among authors: maehara o. J Med Virol. 2023 Feb;95(2):e28452. doi: 10.1002/jmv.28452. J Med Virol. 2023. PMID: 36597900
Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.
Sasaki T, Suda G, Ohara M, Hosoda S, Kawagishi N, Kohya R, Yoda T, Maehara O, Ohnishi S, Yoshida S, Fu Q, Yang Z, Tokuchi Y, Kitagataya T, Suzuki K, Nakai M, Sho T, Natsuizaka M, Komukai S, Ogawa K, Sakamoto N. Sasaki T, et al. Among authors: maehara o. Hepatol Res. 2023 Oct;53(10):960-967. doi: 10.1111/hepr.13936. Epub 2023 Jul 3. Hepatol Res. 2023. PMID: 37332115
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
Hosoda S, Suda G, Sho T, Ogawa K, Kimura M, Yang Z, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N. Hosoda S, et al. Among authors: maehara o. Liver Cancer. 2022 Oct 31;12(2):156-170. doi: 10.1159/000527759. eCollection 2023 Jun. Liver Cancer. 2022. PMID: 37325489 Free PMC article.
Overestimated renal function in patients with liver cirrhosis predicts poor prognosis.
Yoshida S, Suda G, Ohara M, Kimura M, Yang Z, Maehara O, Fu Q, Hosoda S, Akinori K, Tokuchi Y, Yamada R, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. Yoshida S, et al. Among authors: maehara o. Hepatol Res. 2022 Jul;52(7):603-613. doi: 10.1111/hepr.13765. Epub 2022 Apr 19. Hepatol Res. 2022. PMID: 35352857
FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma.
Maehara O, Suda G, Natsuizaka M, Shigesawa T, Kanbe G, Kimura M, Sugiyama M, Mizokami M, Nakai M, Sho T, Morikawa K, Ogawa K, Ohashi S, Kagawa S, Kinugasa H, Naganuma S, Okubo N, Ohnishi S, Takeda H, Sakamoto N. Maehara O, et al. Cancer Biol Ther. 2021 Jun 3;22(5-6):372-380. doi: 10.1080/15384047.2021.1939638. Epub 2021 Jul 5. Cancer Biol Ther. 2021. PMID: 34224333 Free PMC article.
Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy.
Kawagishi N, Suda G, Sakamori R, Matsui T, Onozawa M, Yang Z, Yoshida S, Ohara M, Kimura M, Kubo A, Maehara O, Fu Q, Hosoda S, Tokuchi Y, Suzuki K, Nakai M, Sho T, Morikawa K, Natsuizaka M, Ogawa K, Sakai H, Ohnishi S, Baba M, Takehara T, Sakamoto N. Kawagishi N, et al. Among authors: maehara o. Sci Rep. 2022 Oct 7;12(1):16800. doi: 10.1038/s41598-022-21315-z. Sci Rep. 2022. PMID: 36207368 Free PMC article.
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T, Maehara O, Suda G, Natsuizaka M, Kimura M, Shimazaki T, Yamamoto K, Yamada R, Kitagataya T, Nakamura A, Suzuki K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Morikawa K, Ogawa K, Ohnishi S, Sugiyama M, Mizokami M, Takeda H, Sakamoto N. Shigesawa T, et al. Among authors: maehara o. Carcinogenesis. 2021 Feb 11;42(1):58-69. doi: 10.1093/carcin/bgaa049. Carcinogenesis. 2021. PMID: 32449510
Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.
Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, Miyoshi H, Kimura M, Maehara O, Yamada R, Kitagataya T, Yamamoto K, Shigesawa T, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N; NORTE Study Group. Suzuki K, et al. Among authors: maehara o. J Gastroenterol. 2021 Feb;56(2):168-180. doi: 10.1007/s00535-020-01750-3. Epub 2020 Nov 19. J Gastroenterol. 2021. PMID: 33211179
Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
Kawagishi N, Suda G, Yamamoto Y, Baba M, Furuya K, Maehara O, Ohnishi S, Yoshida S, Fu Q, Yang Z, Hosoda S, Tokuchi Y, Kitagataya T, Ohara M, Suzuki K, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N. Kawagishi N, et al. Among authors: maehara o. Viruses. 2023 Jan 7;15(1):181. doi: 10.3390/v15010181. Viruses. 2023. PMID: 36680221 Free PMC article.
45 results